Research Study

An Investigator-initiated, Multicenter, Phase IV, Open-label Study to Evaluate the Biological Basis for Disease Progression in Relapsing-remitting Multiple Sclerosis Patients Treated in Routine Practice With Gilenya for 5 Years
Principal Investigator 
Anthony Traboulsee

Overview

Body Locations and Systems 
ClinicalTrials.gov# 
NCT02137707
Status 
Closed to Recruitment
Study Start/End 
May 14, 2014 to Jun 30, 2017
Locations 
UBC Hospital
Name/Title 
Karina Grigore, Research Coordinator
Phone 
604-822-1756
Email Address 
karina.grigore@ubc.ca
Purpose of Study 

This study will determine whether in RRMS patients receiving Gilenya there is a link between disease progression and biologic markers.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.